Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1637 1646
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18498834 | USING siRNAs AGAINST TAU CIRCULAR RNAS AS A RATIONAL THERAPY FOR ALZHEIMER'S DISEASE | Non-Final OA | University of Kentucky Research Foundation |
| 18251384 | ENHANCEMENT OF PREDICTABLE AND TEMPLATE-FREE GENE EDITING BY THE ASSOCIATION OF CAS WITH DNA POLYMERASE | Non-Final OA | New York University |
| 18278196 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18265756 | STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 18484001 | MICRORNA COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF NERVOUS SYSTEM DYSFUNCTION | Non-Final OA | Rutgers, The State University of New Jersey |
| 18263194 | COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18260456 | METHODS AND COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY | Non-Final OA | Sardocor Corp. |
| 18267885 | RNAI AGENT FOR INHIBITING HBV EXPRESSION AND USE THEREOF | Non-Final OA | OliX Pharmaceuticals, Inc. |
| 18036594 | NOVEL STEROID HORMONE LIGAND ASSAYS | Non-Final OA | InsituGen Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy